Lara W Katzin

Pompe Disease: A Review of the Current Diagnosis and Treatment Recommendations in the Era of Enzyme Replacement Therapy

A. Amato, Lara W Katzin, 2008, Journal of clinical neuromuscular disease.

The Test Emg and Nerve Conduction Studies in Clinical Practice

R. Chichkova, Lara W Katzin, 2022 .

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Medical marijuana in neurology

S. Benbadis, T. Zesiewicz, Amanda G. Smith, 2014, Expert review of neurotherapeutics.

Medical marijuana.

S. Benbadis, T. Zesiewicz, J. Sanchez-Ramos, 2010, Time.

Lessons learned from INSIGHTS neuropathy study

G. Badger, M. Mayo, J. DiStefano, 2022 .

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Cerebral infarction in Duchenne muscular dystrophy.

Sendhil Krishnan, R. Behrouz, N. Tsakadze, 2011, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Lessons learned from INSIGHTS neuropathy study

G. Badger, M. Mayo, J. DiStefano, 2022 .